Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 10.11.2025 1 AJR Am J Roentgenol 5 Am J Gastroenterol 1 BMC Cancer 1 Cancer 1 Cancer Res 4 Clin Res Hepatol Gastroenterol 1 Dig Dis 1 Endoscopy 1 Eur J Pediatr 1 Eur Radiol 1 Gut 3 Hepatology 2 Int J Cancer 3 J Gastroenterol Hepatol 3 J Hepatol 1 Minerva Gastroenterol (Torino) 1 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHIU SH, Yoon L, Altmayer S, Delitto DJ, et al
   LI-RADS CT/MRI Nonradiation Treatment Response Assessment Version 2024 for Detecting Local Recurrence of Surgically Resected Hepatocellular Carcinoma.
   AJR Am J Roentgenol. 2025 Nov 5. doi: 10.2214/AJR.25.33787.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. BURTON R, Leggio L, Louvet A, Sheron N, et al
   Prevention of Alcohol-Associated Liver Disease.
   Am J Gastroenterol. 2025;120:2487-2501.
   PubMed         Abstract available
   
   
3. JOHN BV, Bastaich D, Mezzacappa C, Ferreira RD, et al
   Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.
   Am J Gastroenterol. 2025;120:2583-2591.
   PubMed         Abstract available
   
   
4. SHENOY A, Jasty VS, Uttal S, Nasser S, et al
   Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients With Advanced Liver Disease.
   Am J Gastroenterol. 2025;120:2576-2582.
   PubMed         Abstract available
   
   
5. NIEZEN S, Morgan TR, Scott D, Yakovchenko V, et al
   Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans.
   Am J Gastroenterol. 2025;120:2559-2566.
   PubMed         Abstract available
   
   
6. SILVEY S, Patel N, Davis BC, Sterling RK, et al
   Use of Natural language processing to objectively identify hepatic encephalopathy in multiple cohorts.
   Am J Gastroenterol. 2025 Nov 6. doi: 10.14309/ajg.0000000000003824.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. BAI J, Zhou J, Zhao X, Hua J, et al
   Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy.
   BMC Cancer. 2025;25:1701.
   PubMed         Abstract available
   
   

   
   Cancer

8. OYENUGA M, McGrew T, Hannan LM, Alese OB, et al
   Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma.
   Cancer. 2025;131:e70162.
   PubMed         Abstract available
   
   

   
   Cancer Res

9. ZHENG Z, Yuan F, Li J, Zhu X, et al
   Gut Microbiota-Mediated Bile Acid Metabolism Regulates Colorectal Cancer Liver Metastasis by Altering Neutrophil Recruitment.
   Cancer Res. 2025 Aug 27. doi: 10.1158/0008-5472.CAN-24-4425.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

10. JIANG J, Yang P, Hou G
    An unusual follicular dendritic cell sarcoma with liver metastasis.
    Clin Res Hepatol Gastroenterol. 2025;49:102707.
    PubMed         Abstract available
    
    
11. ZHU H, Yu J, Luo J, Cai Z, et al
    Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2025;49:102702.
    PubMed         Abstract available
    
    
12. MARICHEZ A, Aldajani N, Fleureau C, Adam JP, et al
    Protecting the fetus during hepatic surgery in pregnancy: the role of cavo-caval bypass.
    Clin Res Hepatol Gastroenterol. 2025;49:102701.
    PubMed         Abstract available
    
    
13. ZAIDI SMM, Irfan Q, Javed R, Khalid Z, et al
    Treatment modalities for metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescent: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2025;49:102685.
    PubMed         Abstract available
    
    

    
    Dig Dis

14. ZHUO Z, Guo Z, Peng H, Ye X, et al
    Cuproptosis-Related lncRNA Risk Model for Hepatocellular Carcinoma Prognosis and Immunotherapy Response.
    Dig Dis. 2025 Nov 6:1-25. doi: 10.1159/000548493.
    PubMed         Abstract available
    
    

    
    Endoscopy

15. HEIDUK TR, Sasse A, Torsello GF, Seif Amir Hosseini A, et al
    Endoscopic ultrasound-guided coil and Histoacryl therapy of varices at the hepaticojejunostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur J Pediatr

16. LOPES JR, Esteves IM, Libonati NB, da Fonte Gomes Silva FMT, et al
    Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis.
    Eur J Pediatr. 2025;184:737.
    PubMed         Abstract available
    
    

    
    Eur Radiol

17. JI C, He Y, Fan Y, Zhu A, et al
    Ultrasound-based fat fraction for detection of hepatic steatosis and quantification of liver fat content using liver biopsy as the reference standard.
    Eur Radiol. 2025 Nov 7. doi: 10.1007/s00330-025-12117.
    PubMed         Abstract available
    
    

    
    Gut

18. CHEN Y, Li W, Wang S, Wang H, et al
    A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis.
    Gut. 2025 Nov 4:gutjnl-2025-336363. doi: 10.1136/gutjnl-2025-336363.
    PubMed         Abstract available
    
    

    
    Hepatology

19. LEI Z, Wu Y, Xue W, Zhu D, et al
    Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001590.
    PubMed         Abstract available
    
    
20. HUA H, Wang D, He L, Chen N, et al
    KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001606.
    PubMed         Abstract available
    
    
21. JIANG Y, Li Y, Wu T, Cao L, et al
    GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
    Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001605.
    PubMed         Abstract available
    
    

    
    Int J Cancer

22. RAJTMAJEROVA M, Ambrozkiewicz F, Hlavac V, Trailin A, et al
    Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases.
    Int J Cancer. 2025 Aug 30. doi: 10.1002/ijc.70116.
    PubMed         Abstract available
    
    
23. SPEHNER L, Bouard A, El Kaddissi A, Kroemer M, et al
    Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo-refractory gastrointestinal cancers.
    Int J Cancer. 2026;158:182-192.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

24. LIU L, Xia Y, Wang B, Zhang Y, et al
    Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2025;40:2659-2673.
    PubMed         Abstract available
    
    
25. LIAO KF, Lai SW
    Aspirin Use and Hepatocellular Carcinoma Risk.
    J Gastroenterol Hepatol. 2025 Nov 6. doi: 10.1111/jgh.70168.
    PubMed        
    
    
26. XIE W
    Letter: A Deep Dive and Future Outlook on the Study of Hypertension's Impact on the Efficacy of Atezolizumab Plus Bevacizumab in Treating Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Nov 5. doi: 10.1111/jgh.70154.
    PubMed        
    
    

    
    J Hepatol

27. JACHS M, Thone P, Odriozola A, Turon F, et al
    Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.
    J Hepatol. 2025 Nov 3:S0168-8278(25)02570-X. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
28. LIU M, Chen M, Weng J, Xu S, et al
    Hepatic LONP1 Overexpression Ameliorates Hepatic Steatosis and Fibrosis in mice.
    J Hepatol. 2025 Oct 31:S0168-8278(25)02607-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
29. MALIK AK, White SA, Mann DA
    Comment on: Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
    J Hepatol. 2025 Oct 31:S0168-8278(25)02606-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    Minerva Gastroenterol (Torino)

30. SIUBA MT, Abushamma A, Qureshi A, Ivary S, et al
    Impact of medical therapy on liver transplant eligibility in patients with portopulmonary hypertension: a systematic review.
    Minerva Gastroenterol (Torino). 2025;71:289-294.
    PubMed         Abstract available
    
    

    
    Oncogene

31. HUANG H, Xiang Y, Deng Y, Liu Q, et al
    WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression.
    Oncogene. 2025 Nov 3. doi: 10.1038/s41388-025-03620.
    PubMed         Abstract available
    
    

    
    PLoS One

32. LEE Y, Lee W
    Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study.
    PLoS One. 2025;20:e0336569.
    PubMed         Abstract available
    
    
33. ISHII M, Itano O, Iwamoto H, Takami Y, et al
    Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.
    PLoS One. 2025;20:e0336230.
    PubMed         Abstract available
    
    
34. LIN J, Huang M, Shen L
    Predictive value of neutrophil to lymphocyte ratio for clinical outcomes in liver cirrhosis: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0335925.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

35. CISOWSKI J, El Zowalaty AE, Sayin SI, Czarnota P, et al
    BRAF inhibition increases TGFbeta2 production and stimulates metastasis in mice with endogenous BRAF(V600E)-induced hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2025;122:e2503044122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

36. SHEN Z, Chen L, Wang L, Dong S, et al
    An Explainable Deep Learning Model for Focal Liver Lesion Diagnosis Using Multiparametric MRI.
    Radiol Artif Intell. 2025 Sep 10:e240531. doi: 10.1148/ryai.240531.
    PubMed         Abstract available
    
    

    
    Transplant Proc

37. TUNCER A, Dirican CD, Sahin E, Ersan V, et al
    Living Donor Liver Transplantation for Iatrogenic Vascular Injury During Laparoscopic Cholecystectomy: Case Report.
    Transplant Proc. 2025 Mar 21:S0041-1345(25)00155.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.